AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 21 min read$KPTI

Abate Kristin sold $450 of KPTI

Abate Kristin (Chief Accounting Officer) sold 378 shares of Karyopharm Therapeutics Inc. (KPTI) at $1.19 on 2026-10-01.

Original reporting
SEC EDGAR · Abate Kristin
Published Oct 2, 2026, 8:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 2, 2026, 8:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$KPTI
Neutral
high confidence
Mentioned
$KPTI
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KPTINeutralLow
01

Why it matters

The disclosed sale is small and unlikely to move the stock significantly.

02

Market read

Routine insider sale with minimal market impact.

03

What to watch

Potential upcoming earnings or other corporate news could dominate price action.

Relevance 3/10Novelty 3/10Timing: after market close on 2026-10-02

Background

SEC Form 4 filing discloses insider transactions for public companies.

Company-level read

Ticker impact

$KPTINeutralHigh confidence
Context

Chief Accounting Officer sold 378 shares for $449.82 on 2026-10-01, reducing holdings to 23,404 shares.

Expected impact

likely slight downward pressure as market prices in the insider sell

Evidence & confidence

The transaction is a routine Form 4 filing with a small dollar amount; such sales typically have minimal impact.

Market effects

Sector

none

Regional

none

Global

none

Counterpoint

What could challenge this read

The sale could be unrelated to company fundamentals and may not affect price.

Key entities

  • company
    Karyopharm Therapeutics Inc.

    Biopharmaceutical company listed on NASDAQ under ticker KPTI.

  • person
    Abate Kristin

    Chief Accounting Officer of Karyopharm Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

KPTI insider trading history →

Related articles

AUG 21
$KPTIHighAI 8/10

Karyopharm’s (KPTI) Big Cancer Bet Faces A Ticking Clock

Karyopharm Therapeutics (KPTI) reported Q2 earnings, highlighting a potential FDA accelerated approval for its myelofibrosis combination therapy, while also facing a cash crunch with funds lasting only until September. The company's selinexor and ruxolitinib combination showed promising results, but a $15.8 million loan payment due soon could trigger a default if not addressed. Karyopharm is exploring financing options and strategic alternatives.

insidermonkey.com3 min
AUG 20
$KPTIMed

Karyopharm (KPTI) Q2 2026 Earnings Call Transcript

Karyopharm (KPTI) reported Q2 2026 revenue of $33.4M, down from $37.9M YoY due to expired agreements. U.S. XPOVIO revenue rose to $30.8M. Net loss was $67M, including non-cash expenses. The company faces a $15.8M debt payment in September, risking a liquidity covenant breach. Management reaffirmed full-year revenue guidance of $130M-$150M and plans to submit an sNDA for selinexor in myelofibrosis.

fool.com2 min
AUG 13
$KPTIHighAI 9/10

It's crunch time for Karyopharm as company faces potential default next month

Karyopharm Therapeutics reported Q2 results showing a $67 million loss and cash reserves of $65.4 million. A $15.8 million loan payment is due Sept. 10, and without financing or a waiver the company says it would breach a $10.0 million liquidity covenant and could default. It is negotiating with lenders and pursuing Xpovio label expansion; Q2 Xpovio sales were $30.8 million.

fiercepharma.com6 min
AUG 13
$KPTIMed

Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission

Karyopharm Therapeutics Inc. (KPTI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission – Planned August sNDA Submission for Selinexor in Combination with Ruxolitinib in Myelofibrosis under the Accelerated Approval Pathway Rema

SEC EDGAR 8-K6 min